This is a StreetInsider.com Premium Only Page

(KZR) – Company Press Releases

Apr 8, 2024 04:01 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Mar 14, 2024 04:01 PM Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Mar 8, 2024 04:05 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Feb 28, 2024 04:01 PM Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024 06:30 PM Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Feb 26, 2024 06:10 PM Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Nov 21, 2023 04:01 PM Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023 04:01 PM Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 3, 2023 04:03 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 9, 2023 05:56 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 3, 2023 04:10 PM Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

Sep 20, 2023 06:30 PM Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southe

Aug 31, 2023 04:01 PM Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Aug 10, 2023 04:01 PM Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 4, 2023 04:03 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jul 7, 2023 04:01 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jun 9, 2023 04:01 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 31, 2023 07:00 AM Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

May 11, 2023 04:01 PM Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 24, 2023 06:10 PM Novo Completes Consolidation of Belltopper Gold Project, Victoria, Australia

Apr 5, 2023 04:01 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 14, 2023 04:01 PM Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Mar 13, 2023 07:00 AM Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

Mar 9, 2023 09:20 AM Novo to Acquire Remaining 50% Interests in Belltopper Gold Project, Victoria, Australia

Mar 6, 2023 07:00 AM Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Mar 3, 2023 06:17 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 1, 2023 04:01 PM Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Feb 6, 2023 04:01 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 13, 2023 04:01 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 4, 2023 04:01 PM Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 7, 2022 04:01 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 18, 2022 08:56 AM Significant Results From Malmsbury Victorian Projects Exploration Update

Nov 14, 2022 07:00 AM Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

Nov 11, 2022 04:01 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Nov 10, 2022 04:01 PM Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 9, 2022 04:01 PM Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Nov 3, 2022 10:00 AM Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting

Oct 14, 2022 07:00 AM Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meetin

Oct 6, 2022 04:01 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 3, 2022 04:01 PM Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

Sep 29, 2022 04:05 PM Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

Sep 2, 2022 04:30 PM Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 1, 2022 07:00 AM Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Aug 11, 2022 04:01 PM Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 3, 2022 04:30 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jul 11, 2022 04:30 PM Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

Jul 7, 2022 04:30 PM Kezar Life Sciences to Present at the William Blair Biotech Focus Conference

Jul 6, 2022 04:30 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 27, 2022 04:01 PM Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

Jun 3, 2022 04:30 PM Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)